Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565298 | 0.81 | RIPK1 (0.67) | RIPK1 | |
| SCHEMBL21800488 | 0.80 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20565016 | 0.80 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL3280126 | 0.77 | RIPK1 (0.42) | RIPK1PARP1CREBBP | |
| SCHEMBL20565680 | 0.76 | RIPK1 (0.51) | RIPK1 | |
| SCHEMBL22981614 | 0.75 | RIPK1 (0.40) | RIPK1 | |
| SCHEMBL16004982 | 0.70 | PARP1 (0.54) | RIPK1PARP1 | |
| SCHEMBL15055636 | 0.69 | RIPK1 (0.46) | RIPK1GPR142PIK3CA | |
| SCHEMBL3789225 | 0.69 | RIPK1 (0.46) | RIPK1CREBBPGPR142PIK3CA | |
| SCHEMBL21800437 | 0.66 | RIPK1 (0.49) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885PARP1 796/4885CREBBP 783/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885PARP1 796/4885CREBBP 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.